Cynata Therapeutics Limited

Equities

CYP

AU000000CYP7

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 02:10:46 2024-04-30 am EDT			5-day change	1st Jan Change
0.21 ^AUD	0.00%		0.00%	+68.00%

Apr. 08	Cynata Therapeutics Limited Completes Patient Enrolment in CYP-006TK Diabetic Foot Ulcer Clinical Trial	CI
Apr. 08	Cynata Therapeutics Concludes Patient Enrolment in Diabetic Foot Ulcer Wound Dressing Product Trial	MT

Cynata Therapeutics Limited Announces Resignation of David Atkins as Director

October 08, 2023 at 05:58 pm EDT

Cynata Therapeutics Limited that Dr. David Atkins has informed the Board that he will not be standing for re-election as a Director at the Company's Annual General Meeting (AGM) to be held on 13 November 2023 and accordingly
will cease to be a Director from the conclusion of the AGM.

Latest news about Cynata Therapeutics Limited

Cynata Therapeutics Limited Completes Patient Enrolment in CYP-006TK Diabetic Foot Ulcer Clinical Trial	Apr. 07	CI
Cynata Therapeutics Concludes Patient Enrolment in Diabetic Foot Ulcer Wound Dressing Product Trial	Apr. 07	MT
Cynata Therapeutics Receives EU Approval for CYP-001 Phase 2 Trial	Mar. 19	MT
Cynata Therapeutics Doses First Patient in Phase Two Trial of Cellular Therapy; Shares Rise 5%	Mar. 04	MT
Cynata Therapeutics Limited Announces Updates on Phase 2 Clinical Trial of CYP-001	Mar. 04	CI
Cynata Therapeutics Names Chief Business Officer; Shares Plunge 14%	Feb. 28	MT
Cynata Therapeutics Limited Announces Initial Data from CYP-006TK Diabetic Foot Ulcer Clinical Trial	Feb. 26	CI
Cynata Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 22	CI
Cynata Therapeutics Expects Initial Results in Diabetic Foot Ulcer Topical Wound Dressing Trial in Q1 2024	Dec. 27	MT
Cynata Therapeutics Completes Recruitment for Phase Three Osteoarthritis Trial	Dec. 12	MT
Cynata Therapeutics Secures Approval in Turkey for Phase 2 Trial of HR-aGvHD; Shares Jump 9%	Dec. 07	MT
Cynata Therapeutics Receives AU$2.3 Million R&D Tax Rebate	Nov. 13	MT
Cynata Therapeutics Secures Clearance to Advance Phase Three Knee Pain Trial	Nov. 06	MT
Cynata Therapeutics Limited Announces Resignation of David Atkins as Director	23-10-08	CI
Cynata Therapeutics Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-28	CI
Cynata Therapeutics Opens Enrollment for Phase Two Cell Therapy Trial	23-08-10	MT
Cynata Therapeutics Taps COO for CEO/Managing Director Role; Shares Down 4%	23-06-30	MT
Cynata Therapeutics Limited Announces Management Appointments	23-06-29	CI
Cynata Therapeutics Limited Announces Chief Executive Officer Changes	23-06-29	CI
Cynata Therapeutics Completes Oversubscribed Share Purchase Plan	23-05-10	MT
Cynata Therapeutics Secures Ethics Approval for Phase Two Trial	23-04-12	MT
Cynata Therapeutics to Raise AU$5 Million Via Share Placement	23-04-06	MT
Cynata Therapeutics Adds Three New Sites for DFU Clinical Trial	23-03-16	MT
Cynata Therapeutics Limited Adds New Sites for DFU Clinical Trial	23-03-15	CI
Cynata Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2022	23-02-27	CI

Chart Cynata Therapeutics Limited

Duration

Period

More charts

Company Profile

Cynata Therapeutics Limited is an Australia-based clinical-stage stem cell and regenerative medicine company. The Company is focused on the development of therapies based on Cymerus, which is a therapeutic stem cell platform technology. Cymerus uses induced pluripotent stem cells and a precursor cell, mesenchymoangioblast (MCA) to manufacture cell therapy products, including mesenchymal stem cells, on a commercial scale. Its lead product candidate, CYP-001, is under Phase I trial and developed for the treatment of steroid-resistant acute graft-versus-host disease (GvHD). Clinical trials of Cymerus products in osteoarthritis, which is under Phase III trial, and diabetic foot ulcers (DFU) are ongoing. In addition, the Company has demonstrated the utility of its Cymerus technology in preclinical models of various diseases, including critical limb ischaemia, idiopathic pulmonary fibrosis, asthma, heart attack, sepsis, acute respiratory distress syndrome and other.

Sector

Biotechnology & Medical Research

Calendar

2024-08-21 - Q4 2024 Earnings Release (Projected)

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
CYNATA THERAPEUTICS LIMITED	+68.00%	24.74M
VERTEX PHARMACEUTICALS INCORPORATED	-3.46%	102B
REGENERON PHARMACEUTICALS, INC.	+1.41%	96.29B
ARGENX SE	+2.13%	22.18B
BIONTECH SE	-15.84%	21.2B
GENMAB A/S	-9.21%	18.31B
WUXI APPTEC CO., LTD.	-39.98%	17.38B
BEIGENE, LTD.	-14.65%	16.36B
NEUROCRINE BIOSCIENCES, INC.	+4.39%	13.97B
SAREPTA THERAPEUTICS, INC.	+31.35%	12.17B

Bio Therapeutic Drugs